Shares of Neon Therapeutics Inc (NASDAQ:NTGN) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $4.31 and last traded at $4.36, with a volume of 1400 shares traded. The stock had previously closed at $4.50.
Several analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Neon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 9th. ValuEngine downgraded shares of Neon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Neon Therapeutics currently has an average rating of “Buy” and a consensus target price of $17.88.
Neon Therapeutics (NASDAQ:NTGN) last posted its quarterly earnings results on Monday, November 12th. The company reported ($0.67) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.12. On average, research analysts expect that Neon Therapeutics Inc will post -4.5 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4116111/neon-therapeutics-ntgn-sets-new-52-week-low-at-4-31.html.
Neon Therapeutics Company Profile (NASDAQ:NTGN)
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
See Also: Hedge Funds – Risk or Reward?
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.